Global Insulin Delivery Devices Market Outlook 2018
In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of RNCOS’ current study.
In our latest research study “Global Insulin Delivery Devices Market Outlook 2018”, RNCOS’ analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. The market, which stood at US$ 10.4 Billion in 2013, is expected to grow at a CAGR of 8.5% during 2013-2018.
Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment’s growth, and the future outlook of the segments. The analysis will help readers to assess the current market penetration for various devices in different regions, which vary significantly due to consumer preferences.
RNCOS’ study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market.
In our latest research study “Global Insulin Delivery Devices Market Outlook 2018”, RNCOS’ analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. The market, which stood at US$ 10.4 Billion in 2013, is expected to grow at a CAGR of 8.5% during 2013-2018.
Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment’s growth, and the future outlook of the segments. The analysis will help readers to assess the current market penetration for various devices in different regions, which vary significantly due to consumer preferences.
RNCOS’ study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL INSULIN MARKET OVERVIEW TO 2018
4. INDUSTRY TRENDS AND DRIVERS
4.1 Rising Popularity of Artificial Pancreas
4.2 Home Infusion Therapy Gaining Importance in Treatment of Diabetes
4.3 Modifications in Insulin Delivery through Nanoparticles and Polymers
4.4 Increasing Prevalence of Diabetes
4.5 Rising Awareness among People about Diabetes Care
4.6 Improved Access and Lower Insulin Prices in the Developing World
4.7 Asian Markets Offer Considerable Growth Potential
5. KEY MARKET RESTRAINTS
5.1 Risk and Complications Associated with Delivery of Insulin
5.2 High Cost of Insulin Analog
5.3 Traditional Remedies for Diabetes Care
6. GLOBAL INSULIN DELIVERY DEVICES MARKET OUTLOOK TO 2018
6.1 US
6.1.1 Prevalence
6.1.2 Market Analysis
6.1.3 Regulatory Overview
6.2 Japan
6.2.1 Prevalence
6.2.2 Market Analysis
6.2.3 Regulatory Overview
6.3 China
6.3.1 Prevalence
6.3.2 Market Analysis
6.3.3 Regulatory Overview
6.4 Brazil
6.4.1 Prevalence
6.4.2 Market Analysis
6.4.3 Regulatory Overview
6.5 India
6.5.1 Prevalence
6.5.2 Market Analysis
6.5.3 Regulatory Overview
7. INSULIN DELIVERY DEVICES: CURRENT AND FUTURE OUTLOOK TO 2018
7.1 Insulin Pens
7.1.1 Mechanism and Technologies
7.1.2 Pros and Cons
7.1.3 Market Analysis
7.1.4 Key Players and Products
7.2 Insulin Pumps
7.2.1 Mechanism and Technologies
7.2.2 Pros and Cons
7.2.3 Market Analysis
7.2.4 Key Players and Products
7.3 Insulin Syringes
7.3.1 Mechanism and Technologies
7.3.2 Pros and Cons
7.3.3 Market Analysis
7.3.4 Key Players and Products
7.4 Insulin Jet Injectors
7.4.1 Mechanism and Technologies
7.4.2 Pros and Cons
7.4.3 Market Analysis
7.4.4 Key Players and Products
8. EMERGING DEVICES
8.1 Implantable Insulin Pumps
8.2 Insulin Inhalers
8.3 Oral Insulin/Insulin Pill
8.4 Insulin Patch
9. KEY PLAYERS
9.1 Novo Nordisk
9.2 Eli Lilly
9.3 Medtronic
9.4 Becton Dickinson
9.5 Sanofi-Aventis
9.6 F. Hoffmann La Roche
9.7 Insulet Corporation
9.8 Ypsomed Holding AG
9.9 Johnson and Johnson
9.10 B. Braun Melsungen AG
9.11 Abbott Laboratories
2. RESEARCH METHODOLOGY
3. GLOBAL INSULIN MARKET OVERVIEW TO 2018
4. INDUSTRY TRENDS AND DRIVERS
4.1 Rising Popularity of Artificial Pancreas
4.2 Home Infusion Therapy Gaining Importance in Treatment of Diabetes
4.3 Modifications in Insulin Delivery through Nanoparticles and Polymers
4.4 Increasing Prevalence of Diabetes
4.5 Rising Awareness among People about Diabetes Care
4.6 Improved Access and Lower Insulin Prices in the Developing World
4.7 Asian Markets Offer Considerable Growth Potential
5. KEY MARKET RESTRAINTS
5.1 Risk and Complications Associated with Delivery of Insulin
5.2 High Cost of Insulin Analog
5.3 Traditional Remedies for Diabetes Care
6. GLOBAL INSULIN DELIVERY DEVICES MARKET OUTLOOK TO 2018
6.1 US
6.1.1 Prevalence
6.1.2 Market Analysis
6.1.3 Regulatory Overview
6.2 Japan
6.2.1 Prevalence
6.2.2 Market Analysis
6.2.3 Regulatory Overview
6.3 China
6.3.1 Prevalence
6.3.2 Market Analysis
6.3.3 Regulatory Overview
6.4 Brazil
6.4.1 Prevalence
6.4.2 Market Analysis
6.4.3 Regulatory Overview
6.5 India
6.5.1 Prevalence
6.5.2 Market Analysis
6.5.3 Regulatory Overview
7. INSULIN DELIVERY DEVICES: CURRENT AND FUTURE OUTLOOK TO 2018
7.1 Insulin Pens
7.1.1 Mechanism and Technologies
7.1.2 Pros and Cons
7.1.3 Market Analysis
7.1.4 Key Players and Products
7.2 Insulin Pumps
7.2.1 Mechanism and Technologies
7.2.2 Pros and Cons
7.2.3 Market Analysis
7.2.4 Key Players and Products
7.3 Insulin Syringes
7.3.1 Mechanism and Technologies
7.3.2 Pros and Cons
7.3.3 Market Analysis
7.3.4 Key Players and Products
7.4 Insulin Jet Injectors
7.4.1 Mechanism and Technologies
7.4.2 Pros and Cons
7.4.3 Market Analysis
7.4.4 Key Players and Products
8. EMERGING DEVICES
8.1 Implantable Insulin Pumps
8.2 Insulin Inhalers
8.3 Oral Insulin/Insulin Pill
8.4 Insulin Patch
9. KEY PLAYERS
9.1 Novo Nordisk
9.2 Eli Lilly
9.3 Medtronic
9.4 Becton Dickinson
9.5 Sanofi-Aventis
9.6 F. Hoffmann La Roche
9.7 Insulet Corporation
9.8 Ypsomed Holding AG
9.9 Johnson and Johnson
9.10 B. Braun Melsungen AG
9.11 Abbott Laboratories
LIST OF FIGURES:
Figure 3-1: Global - Number of Diabetic Patients (Million), 2013 & 2030
Figure 3-2: Global - Insulin Market (Billion US$), 2013-2018
Figure 3-3: Global - Insulin Market by Type of Packaging (%), 2013
Figure 3-4: Global - Insulin Market by Region (%), 2013
Figure 3-5: Global - Insulin Market by Player (%), 2013
Figure 6-1: Global - Insulin Delivery Devices Market (Billion US$), 2013-2018
Figure 6-2: Global - Insulin Delivery Devices Market by Segment (%), 2013
Figure 6-3: US - Insulin Delivery Devices Market (Billion US$), 2013-2018
Figure 6-4: US - Insulin Delivery Devices Market by Segment (%), 2013
Figure 6-5: US - Insulin Delivery Devices Market by Segment (%), 2018
Figure 6-6: US - Insulin Pen Market (Billion US$), 2013-2018
Figure 6-7: US - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-8: US - Insulin Pump Market (Million US$), 2013-2018
Figure 6-9: US - Insulin Jet Injector Market (Million US$), 2013-2018
Figure 6-10: Japan - Insulin Delivery Devices Market (Billion US$), 2013-2018
Figure 6-11: Japan - Insulin Pen Market (Million US$), 2013-2018
Figure 6-12: Japan - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-13: China - Insulin Delivery Devices Market (Million US$), 2013-2018
Figure 6-14: China - Insulin Pen Market (Million US$), 2013-2018
Figure 6-15: China - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-16: Brazil - Insulin Delivery Devices Market (Million US$), 2013-2018
Figure 6-17: Brazil - Insulin Pen Market (Million US$), 2013-2018
Figure 6-18: Brazil - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-19: India - Insulin Delivery Devices Market (Million US$), 2013-2018
Figure 6-20: India - Insulin Pen Market (Million US$), 2013-2018
Figure 6-21: India - Insulin Syringe Market (Million US$), 2013-2018
Figure 7-1: Global - Insulin Pen Market (Billion US$), 2013-2018
Figure 7-2: Global - Insulin Pen Market by Region (%), 2013
Figure 7-3: Global - Insulin Pen Market by Region (%), 2018
Figure 7-4: Global - Insulin Pump Market (Million US$), 2013-2018
Figure 7-5: Global - Share of Medtronic in Insulin Pumps Market (2010)
Figure 7-6: Global - Insulin Syringes Market (Million US$), 2013-2018
Figure 7-7: Global - Insulin Syringes Market by Region (%), 2013
Figure 7-8: Global - Insulin Syringes Market by Region (%), 2018
Figure 7-9: Global - Insulin Jet Injectors Market (Million US$), 2013-2018
Figure 9-1: Novo Nordisk - Share of Diabetic Products of by Value (2013)
Figure 9-2: Novo Nordisk - Sales by Geographic Regions (%), 2013
Figure 9-3: Eli Lilly - Sales by Business Segments (%), 2013
Figure 9-4: Eli Lilly - Sales by Geographic Regions (%), 2013
Figure 9-5: Medtronic - Sales by Business Segments (%), 2013
Figure 9-6: Medtronic - Sales by Geographic Regions (%), 2013
Figure 9-7: BD Global - Sales by Business Segments (%), 2013
Figure 9-8: BD Medical - Sales by Business Segments (%), 2013
Figure 9-9: BD Global - Sales by Geographic Regions (%), 2013
Figure 9-10: Sanofi-Aventis - Sales by Geographic Regions (%), 2013
Figure 9-11: Roche - Sales by Business Segments (%), 2013
Figure 9-12: Roche - Sales of In-Vitro Diagnostics by Segments (%), 2013
Figure 9-13: Roche - Sales by Geographic Regions (%), 2013
Figure 9-14: Ypsomed - Sales by Geographic Regions (%), 2013
Figure 9-15: J&J - Sales by Business Segments (%), 2013
Figure 9-16: B.Braun - Sales by Geographic Regions (%), 2013
Figure 9-17: Abbott - Sales by Business Segments (%), 2013
Figure 9-18: Abbott - Sales of Medical Devices by Segments (%), 2013
Figure 9-19: Abbott - Sales by Geographic Regions (%), 2013
Figure 3-1: Global - Number of Diabetic Patients (Million), 2013 & 2030
Figure 3-2: Global - Insulin Market (Billion US$), 2013-2018
Figure 3-3: Global - Insulin Market by Type of Packaging (%), 2013
Figure 3-4: Global - Insulin Market by Region (%), 2013
Figure 3-5: Global - Insulin Market by Player (%), 2013
Figure 6-1: Global - Insulin Delivery Devices Market (Billion US$), 2013-2018
Figure 6-2: Global - Insulin Delivery Devices Market by Segment (%), 2013
Figure 6-3: US - Insulin Delivery Devices Market (Billion US$), 2013-2018
Figure 6-4: US - Insulin Delivery Devices Market by Segment (%), 2013
Figure 6-5: US - Insulin Delivery Devices Market by Segment (%), 2018
Figure 6-6: US - Insulin Pen Market (Billion US$), 2013-2018
Figure 6-7: US - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-8: US - Insulin Pump Market (Million US$), 2013-2018
Figure 6-9: US - Insulin Jet Injector Market (Million US$), 2013-2018
Figure 6-10: Japan - Insulin Delivery Devices Market (Billion US$), 2013-2018
Figure 6-11: Japan - Insulin Pen Market (Million US$), 2013-2018
Figure 6-12: Japan - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-13: China - Insulin Delivery Devices Market (Million US$), 2013-2018
Figure 6-14: China - Insulin Pen Market (Million US$), 2013-2018
Figure 6-15: China - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-16: Brazil - Insulin Delivery Devices Market (Million US$), 2013-2018
Figure 6-17: Brazil - Insulin Pen Market (Million US$), 2013-2018
Figure 6-18: Brazil - Insulin Syringe Market (Million US$), 2013-2018
Figure 6-19: India - Insulin Delivery Devices Market (Million US$), 2013-2018
Figure 6-20: India - Insulin Pen Market (Million US$), 2013-2018
Figure 6-21: India - Insulin Syringe Market (Million US$), 2013-2018
Figure 7-1: Global - Insulin Pen Market (Billion US$), 2013-2018
Figure 7-2: Global - Insulin Pen Market by Region (%), 2013
Figure 7-3: Global - Insulin Pen Market by Region (%), 2018
Figure 7-4: Global - Insulin Pump Market (Million US$), 2013-2018
Figure 7-5: Global - Share of Medtronic in Insulin Pumps Market (2010)
Figure 7-6: Global - Insulin Syringes Market (Million US$), 2013-2018
Figure 7-7: Global - Insulin Syringes Market by Region (%), 2013
Figure 7-8: Global - Insulin Syringes Market by Region (%), 2018
Figure 7-9: Global - Insulin Jet Injectors Market (Million US$), 2013-2018
Figure 9-1: Novo Nordisk - Share of Diabetic Products of by Value (2013)
Figure 9-2: Novo Nordisk - Sales by Geographic Regions (%), 2013
Figure 9-3: Eli Lilly - Sales by Business Segments (%), 2013
Figure 9-4: Eli Lilly - Sales by Geographic Regions (%), 2013
Figure 9-5: Medtronic - Sales by Business Segments (%), 2013
Figure 9-6: Medtronic - Sales by Geographic Regions (%), 2013
Figure 9-7: BD Global - Sales by Business Segments (%), 2013
Figure 9-8: BD Medical - Sales by Business Segments (%), 2013
Figure 9-9: BD Global - Sales by Geographic Regions (%), 2013
Figure 9-10: Sanofi-Aventis - Sales by Geographic Regions (%), 2013
Figure 9-11: Roche - Sales by Business Segments (%), 2013
Figure 9-12: Roche - Sales of In-Vitro Diagnostics by Segments (%), 2013
Figure 9-13: Roche - Sales by Geographic Regions (%), 2013
Figure 9-14: Ypsomed - Sales by Geographic Regions (%), 2013
Figure 9-15: J&J - Sales by Business Segments (%), 2013
Figure 9-16: B.Braun - Sales by Geographic Regions (%), 2013
Figure 9-17: Abbott - Sales by Business Segments (%), 2013
Figure 9-18: Abbott - Sales of Medical Devices by Segments (%), 2013
Figure 9-19: Abbott - Sales by Geographic Regions (%), 2013
LIST OF TABLES:
Table 3-1: Global - Diabetic Population of Top 10 Countries (Million), 2013 & 2030
Table 4-1: Commercially available Insulin Pumps
Table 5-1: Risk factors associated with Insulin Pumps
Table 5-2: Risk factors associated with Insulin Pen
Table 6-1: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-2: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-3: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-4: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-5: India - Diabetic Patients in Age Group 20-79 Years (‘000), 2013 & 2030
Table 7-1: Global - Key Insulin Pen Products by Company
Table 7-2: Global - Key Insulin Syringes Products by Company
Table 9-1: Novo Nordisk - Sales by Business Segments (Million US$), 2011-2013
Table 9-2: Novo Nordisk - Diabetes Product Sales by Geographic Regions (Million US$), 2011-2013
Table 9-3: Eli Lilly - Sales by Business Segments (Million US$), 2011-2013
Table 9-4: Eli Lilly - Sales by Geographic Regions (Million US$), 2011-2013
Table 9-5: Medtronic - Sales by Business Segments (Million US$), 2011-2013
Table 9-6: BD Global - Sales by Business Segments (Million US$), 2011-2013
Table 9-7: BD Medical - Sales by Business Segments (Million US$), 2011-2013
Table 9-8: Sanofi-Aventis - Sales by Business Segments (Million US$), 2011-2013
Table 9-9: Insulet Corporation - Sales of Insulin Pumps (Million US$), 2011-2013
Table 9-10: J&J - Sales by Business Segments (Million US$), 2011-2013
Table 9-11: J&J - Sales of Medical Devices & Diagnostics by Segments (Million US$), 2011-2013
Table 3-1: Global - Diabetic Population of Top 10 Countries (Million), 2013 & 2030
Table 4-1: Commercially available Insulin Pumps
Table 5-1: Risk factors associated with Insulin Pumps
Table 5-2: Risk factors associated with Insulin Pen
Table 6-1: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-2: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-3: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-4: Brazil - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
Table 6-5: India - Diabetic Patients in Age Group 20-79 Years (‘000), 2013 & 2030
Table 7-1: Global - Key Insulin Pen Products by Company
Table 7-2: Global - Key Insulin Syringes Products by Company
Table 9-1: Novo Nordisk - Sales by Business Segments (Million US$), 2011-2013
Table 9-2: Novo Nordisk - Diabetes Product Sales by Geographic Regions (Million US$), 2011-2013
Table 9-3: Eli Lilly - Sales by Business Segments (Million US$), 2011-2013
Table 9-4: Eli Lilly - Sales by Geographic Regions (Million US$), 2011-2013
Table 9-5: Medtronic - Sales by Business Segments (Million US$), 2011-2013
Table 9-6: BD Global - Sales by Business Segments (Million US$), 2011-2013
Table 9-7: BD Medical - Sales by Business Segments (Million US$), 2011-2013
Table 9-8: Sanofi-Aventis - Sales by Business Segments (Million US$), 2011-2013
Table 9-9: Insulet Corporation - Sales of Insulin Pumps (Million US$), 2011-2013
Table 9-10: J&J - Sales by Business Segments (Million US$), 2011-2013
Table 9-11: J&J - Sales of Medical Devices & Diagnostics by Segments (Million US$), 2011-2013
